EFFICACY DATA FOR CROHN'S DISEASE

Proven to Give Patients a Chance at Endoscopic Control and Durable Remission in Crohn's^1,2

In clinical trials, Skyrizi helped with the following: Early symptoms relief: patients achieved symptom relief with clinical response achieved as early as week 4 and clinical remission at weeks 4 and 12. Endoscopic control: patients achieved endoscopic remission and endoscopic response at weeks 12 and 52, with data observed at weeks 152 and 248. And durable remission: patients achieved clinical remission at week 52, with data observed at weeks 152 and 248.

*Based on data from trials with SKYRIZI IV.

^¶Endoscopic remission at Week 52 was not statistically significant under the prespecified multiple testing procedure.

^#Week 152 and 248 data is based on not statistically significant, as-observed data. No conclusions can be made.

Patients Achieved Visible Improvement of the Intestinal Lining and Clinical Remission^‡ at Weeks 12 and 52^1,5

Composite chart showing co-primary endpoints in SKYRIZI Crohn’s disease studies. Endoscopic response and clinical remission rates were higher with SKYRIZI than placebo in the ADVANCE and MOTIVATE induction studies and were maintained through Week 52 in the FORTIFY maintenance study.

STUDY DESIGNS

ADVANCE (N=850) and MOTIVATE (N=569) IV Induction studies were 12-week, randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI in patients with moderately to severely active Crohn’s disease who demonstrated prior treatment failure to conventional (advanced therapy^††-naïve^##) and/or biologic treatment. Patients received an IV infusion of SKYRIZI 600 mg (recommended dose), risankizumab-rzaa 1200 mg, or placebo at Weeks 0, 4, and 8.¹

FORTIFY (N=382) Maintenance study was a 52-week study that evaluated the efficacy and safety of SKYRIZI in patients who achieved clinical response^† (decrease in CDAI ≥100) from SKYRIZI induction in the ADVANCE and MOTIVATE studies. Patients were randomized to SKYRIZI 180 mg SC, SKYRIZI 360 mg SC, or placebo at Week 12 and every 8 weeks thereafter.¹

Use the lowest effective dosage to maintain therapeutic response.

All p-values are SKYRIZI treatment arms vs placebo.

^††Advanced therapy in Crohn’s is defined as biologics.

^§§Placebo (Induction Responders): Patients who achieved CDAI clinical response (CR-100)^† to SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.¹

^†Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

^‡Clinical remission was defined as a CDAI score <150 points.¹

^§Endoscopic remission was defined as a SES-CD ≤4 and at least a 2-point reduction versus baseline and no subscore >1 in any individual variable, as scored by a central reviewer.¹

^IIEndoscopic response is defined as a decrease in SES-CD >50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading. The sections evaluated on endoscopy are the rectum, sigmoid and left colon, transverse colon, right colon, and ileum (per SES-CD assessment).¹

**The mixed population includes patients who had inadequate response, loss of response, or intolerance to one or more biologics (advanced therapy failure), as well as patients who were bio-exposed but did not have an inadequate response, loss of response, or intolerance to biologics (biologic naïve).¹

^‡‡Prior advanced therapy failure includes inadequate response, loss of response, or intolerance to one or more biologics.¹

^IIIIPatients who responded to placebo in induction (CR-100)^† were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁵

^¶¶Continuous placebo data not intended for direct comparison.⁵

^##The advanced therapy-naïve subpopulation includes patients who were exposed to a biologic but did not have an inadequate response, loss of response, or intolerance to biologics.⁵

CDAI=Crohn's disease activity index; CR=clinical response; IL-23=interleukin-23; IV=intravenous; SC=subcutaneous; SES-CD=simple endoscopic score for Crohn's disease.

EARLY SYMPTOM RELIEF

SKYRIZI Is the Only IL-23i to Achieve Symptom Relief at Week 4 in Crohn’s IV Pivotal Trials^1,3,6

Clinical Response* (CDAI CR-100) at Weeks 4, 8, 12^1,3,6

Line graph showing clinical response rates through Week 12. Response rates increased from 41% at Week 4 to 53% at Week 8 and 60% at Week 12 with SKYRIZI 600 mg IV, compared with 25%, 32%, and 37% with placebo.

DATA LIMITATIONS: Data not labeled as a ranked secondary endpoint were prespecified nonranked endpoints not controlled for multiplicity; therefore, treatment differences could represent chance findings. No conclusions regarding these comparisons can be made.

*Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

Remission as Early as Week 4⁶

Clinical Remission^† at Weeks 4, 8, 12^3,6

Line graph showing clinical remission rates through Week 12. Rates increased from 18% at Week 4 to 35% at Week 8 and 45% at Week 12 with SKYRIZI 600 mg IV, compared with 10%, 17%, and 25% with placebo.

Clinical remission rates in the MOTIVATE study were higher with SKYRIZI 600 mg IV than placebo, reaching 21% versus 11% at Week 4, 33% versus 13% at Week 8, and 42% versus 20% at Week 12.

DATA LIMITATIONS: Data at Week 8 were nonranked endpoints not controlled for multiplicity; therefore, treatment differences could represent chance findings. No conclusions regarding these comparisons can be made.

SKYRIZI is the only IL-23–specific inhibitor that achieved clinical remission^† at Week 4 in Crohn’s disease IV pivotal trials^1,3,6

^†Clinical remission was defined as a CDAI score <150 points.¹

CDAI=Crohn's disease activity index; CR=clinical response; IL-23=interleukin-23; IL-23i=interleukin-23 inhibitor; IV=intravenous.

OPEN-LABEL EXTENSION (OLE) STUDY DESIGN

FORTIFY-OLE is an ongoing, multicenter, open-label extension study that evaluated long-term efficacy and safety of SKYRIZI that included patients from the FORTIFY maintenance study. Patients in the FORTIFY maintenance study achieved clinical response* with SKYRIZI in the ADVANCE and MOTIVATE IV induction studies. This study population for FORTIFY-OLE is a sub-analysis that includes all randomized subjects who had a baseline eligibility SES-CD of ≥6 (≥4 for isolated ileal disease), received SKYRIZI 600 mg IV for 12 weeks in the induction studies, and have received at least one dose of SKYRIZI 180 mg or 360 mg SC in the Phase 3 maintenance study FORTIFY and at least one dose of SKYRIZI 180 mg SC in the FORTIFY-OLE study.^1,2

*Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

ENDOSCOPIC CONTROL

Visible Improvement of the Intestinal Lining Up to ~5 years

**Endoscopic Remission* Seen at Weeks 12, 52, 152, and 248^1,2,4,5**

Week 12 endoscopic remission rates were higher with SKYRIZI than placebo in both induction studies: 24% versus 9% in ADVANCE and 19% versus 4% in MOTIVATE.

Bar chart showing endoscopic remission rates in Crohn’s disease studies. At Week 52, rates were 41% with SKYRIZI 360 mg SC versus 13% with placebo and 13% with continuous placebo in the total population and 53% versus 19% in the advanced therapy-naive subgroup. Rates observed during extension follow-up were 64% at Week 152 and 70% at Week 248 with SKYRIZI.

Results at 52 weeks are among 382 patients who achieved clinical response^# after 12 weeks of treatment with SKYRIZI in IV induction trials.

Use the lowest effective dosage to maintain therapeutic response.

^¶Continuous placebo data not intended for direct comparison.⁵

DATA LIMITATIONS: Endoscopic remission at Week 52 was not statistically significant. Subgroup data were not tested for multiplicity control, so no difference in treatment effect for SKYRIZI vs placebo can be concluded. At Weeks 152 and 248, endoscopy scores were locally read. OLE LIMITATIONS: All patients completed the 52-week maintenance period and received SKYRIZI 180 mg Q8W regardless of the maintenance dose. An OLE may enrich long-term data as patients intolerant or unresponsive to the drug drop out. AO LIMITATIONS: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates. All observed data were used regardless of premature discontinuation of study drug or initiation of concomitant medication.

*Endoscopic remission was defined as SES-CD ≤4 and at least a 2-point reduction versus baseline and no subscore >1 in any individual variable, as scored by a central reviewer.¹ At Week 152, endoscopy scores were locally read.

^#Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

^†Advanced therapy in Crohn’s is defined as biologics.

^‡The advanced therapy-naïve subpopulation includes patients who were exposed to a biologic but did not have an inadequate response, loss of response, or intolerance to advanced therapies.⁵

^§Placebo (Induction Responders): Patients who achieved CDAI clinical response (CR-100)^# to SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.¹

^||Patients who responded to placebo in induction (CR-100)^# were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁵

CDAI=Crohn’s disease activity index; CR=clinical response; IV=intravenous; Q8W=every 8 weeks; RCT=randomized controlled trial; SC=subcutaneous; SES-CD=simple endoscopic score for Crohn’s disease.

Endoscopic Response* at Weeks 52, 152, and 248^1,2,4,5

Bar chart showing endoscopic response rates. At Week 52, response rates were 48% with SKYRIZI 360 mg SC versus 22% with placebo and 15% with continuous placebo in the total population and 59% versus 23% in the advanced therapy-naive subgroup. Rates observed during extension follow-up were 78% at Week 152 and 86% at Week 248 with SKYRIZI.

Results at 52 weeks are among 382 patients who achieved clinical response^# after 12 weeks of treatment with SKYRIZI in IV induction trials.

Use the lowest effective dosage to maintain therapeutic response.

^¶Continuous placebodata not intended for direct comparison.⁵

OLE LIMITATIONS: All patients completed the 52-week maintenance period and received SKYRIZI 180 mg Q8W regardless of the maintenance dose. An OLE may enrich long-term data as patients intolerant or unresponsive to the drug drop out. AO LIMITATIONS: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates. All observed data were used regardless of premature discontinuation of study drug or initiation of concomitant medication.

*Endoscopic response was defined as a decrease in SES-CD >50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading. The sections evaluated on endoscopy are the rectum, sigmoid and left colon, transverse colon, right colon, and ileum (per SES-CD assessment).¹

^†Advanced therapy in Crohn’s is defined as biologics.

^‡The advanced therapy-naïve subpopulation includes patients who were exposed to a biologic but did not have an inadequate response, loss of response, or intolerance to advanced therapies.⁵

^§Placebo (Induction Responders): Patients who achieved CDAI clinical response (CR-100)^#to SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.¹

^||Patients who responded to placebo in induction (CR-100)^# were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁵

^#Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

CDAI=Crohn's disease activity index; CR=clinical response; Q8W=every 8 weeks; RCT=randomized controlled trial; SC=subcutaneous; SES-CD=simple endoscopic score for Crohn's disease.

DURABLE REMISSION

Durable Remission at 1 Year

**Clinical Remission* at Week 52^1,5**

Bar chart showing clinical remission rates. At Week 52, remission rates were 57% with SKYRIZI 360 mg SC versus 46% with placebo and 23% continuous placebo in the total population and 71% versus 65% in the advanced therapy-naive subgroup.

Results at 52 weeks are among 382 patients who achieved clinical response^#after 12 weeks of treatment with SKYRIZI in IV induction trials.

^¶Continuous placebodata not intended for direct comparison.⁵

*Clinical remission is defined as a CDAI score <150 points.¹

^†Advanced therapy in Crohn’s is defined as biologics.

^‡The advanced therapy-naïve subpopulation includes patients who were exposed to a biologic but did not have an inadequate response, loss of response, or intolerance to advanced therapies.⁵

^§Placebo (Induction Responders): Patients who achieved CDAI clinical response (CR-100)^#to SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.¹

^||Patients who responded to placebo in induction (CR-100)^# were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁵

^#Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

CDAI=Crohn's disease activity index; CR=clinical response; RCT=randomized controlled trial; SC=subcutaneous.

Consistent Rates of Clinical Remission* Up to ~5 Years^1,2,4

Based on FORTIFY Post Hoc Analyses (As Observed [AO])

Clinical response^† to SKYRIZI required after 12 weeks of IV induction to enter FORTIFY¹

Line graph showing clinical remission rates through Week 248.

of advanced therapy^‡-naïve^§patients in the OLE experienced clinical remission* at ~5 years²

^§The advanced therapy-naïve subpopulation includes patients who were exposed to a biologic but did not have an inadequate response, loss of response, or intolerance to advanced therapies.⁵

*Clinical remission is defined as a CDAI score <150 points.¹

^†Clinical response was defined as a reduction of CDAI score ≥100 points from baseline.¹

^‡Advanced therapy in Crohn’s is defined as biologics.

CDAI=Crohn’s disease activity index; CR=clinical response; OLE=open-label extension; Q8W=every 8 weeks; SC=subcutaneous.

Recommended for You

SC Induction Data

Explore SC Induction Data

Head-to-Head Trial

Explore H2H Data

SKYRIZI Dosing

View Dosing Info

AFFIRM	SKYRIZI 720 mg SCN=180	Placebo N=94
Male, n (%)	103 (57.2)	53 (56.4)
Age (years), mean (SD)	40 (14.1)	38.6 (14.8)
Disease duration (years), mean (SD)	8.7 (9.0)	7.1 (8.0)
Disease location
Ileal only, n (%)	21 (11.7)	15 (16.0)
Colonic only, n (%)	58 (32.2)	30 (31.9)
Ileal-colonic, n (%)	101 (56.1)	49 (52.1)
hs-CRP (mg/L), median (min, max)	5.35 (0.2, 120.5)	5.15 (0.2, 129.4)
CDAI, mean (SD)	311.9 (54.3)	314.2 (55.5)
SES-CD, mean (SD)	13.3 (6.5)	12.7 (6.5)
Corticosteroid use, n (%)	43 (23.9)	25 (26.6)
*Advanced therapy failure history**
0, n (%)	65 (36.1)	33 (35.1)
1, n (%)	58 (32.2)	30 (31.9)
>1, n (%)	57 (31.7)	31 (33.0)

ADVANCE	SKYRIZI 600 mg IVN=336	Placebo N=175
Male, n (%)	189 (56)	88 (50)
Age (years), mean (SD)	38.3 (13.3)	37.1 (13.4)
Disease duration (years), mean (SD)	9.0 (8.8)	8.2 (7.1)
Disease location
Ileal only, n (%)	52 (15)	19 (11)
Colonic only, n (%)	115 (34)	70 (40)
Ileal-colonic, n (%)	169 (50)	86 (49)
hs-CRP (mg/L), median (IQR)	7.3 (2.8-21.8)	8.4 (2.8-21.9)
CDAI, mean (SD)	311.2 (62.4)	319.2 (59.4)
SES-CD, mean (SD)	14.7 (7.7)	13.8 (6.8)
Corticosteroid use, n (%)	102 (30)	50 (29)
*Advanced therapy failure history**
0, n (%)	141 (42)	78 (45)
1, n (%)	100 (30)	41 (23)
>1, n (%)	95 (28)	56 (32)

MOTIVATE	SKYRIZI 600 mg IVN=191	Placebo N=187
Male, n (%)	92 (48)	99 (53)
Age (years), mean (SD)	40.2 (13.6)	39.3 (13.5)
Disease duration (years), mean (SD)	10.9 (7.7)	12.5 (9.7)
Disease location
Ileal only, n (%)	33 (17)	26 (14)
Colonic only, n (%)	75 (39)	73 (39)
Ileal-colonic, n (%)	83 (43)	88 (47)
hs-CRP (mg/L), median (IQR)	9.3 (3.5-23.0)	9.4 (3.6-28.2)
CDAI, mean (SD)	310.7 (63.6)	319.6 (69.8)
SES-CD, mean (SD)	14.4 (7.6)	15.0 (8.1)
Corticosteroid use, n (%)	65 (34)	68 (36)
*Advanced therapy failure history**
0, n (%)	0	0
1, n (%)	92 (48)	88 (47)
>1, n (%)	99 (52)	99 (53)

FORTIFY	SKYRIZI 180 mg SC N=135	SKYRIZI 360 mg SC N=117	Placebo (Induction Responders^†)N=130
Baseline of Induction (ADVANCE, MOTIVATE)
Male, n (%)	62 (45.9)	67 (57.3)	72 (55.4)
Age (years), mean (SD)	39.2 (14.7)	36.2 (12.6)	38.0 (12.8)
Disease duration (years), mean (SD)	10.6 (10.2)	8.6 (7.1)	9.6 (8.2)
Disease location
Ileal only, n (%)	12 (9)	13 (11)	18 (14)
Colonic only, n (%)	63 (47)	52 (44)	49 (38)
Ileal-colonic, n (%)	60 (44)	52 (44)	63 (49)
Baseline immunomodulator use, n (%)	37 (27.4)	34 (29.1)	33 (25.4)
Baseline steroid use, n (%)	47 (34.8)	36 (30.8)	40 (30.8)
*Advanced therapy failure history**
0, n (%)	40 (29.6)	34 (29.1)	31 (23.8)
1, n (%)	34 (25.2)	42 (35.9)	49 (37.7)
>1, n (%)	61 (45.2)	41 (35.0)	50 (38.5)
Baseline CDAI, mean (SD)	327.6 (68.2)	316.2 (59.6)	314.2 (64.2)
Baseline SES-CD, mean (SD)	14.9 (7.2)	14.3 (7.0)	14.1 (7.1)
Baseline SF, mean (SD)	6.2 (3.1)	5.9 (2.7)	5.8 (2.7)
Baseline APS, mean (SD)	2.0 (0.4)	1.9 (0.5)	1.9 (0.5)
Baseline FCP (mg/kg), median (min, max)	1666.0 (30, 28800)	1622.0 (30, 14649)	904.0 (30, 11378)
Baseline hs-CRP (mg/L), median (min, max)	8.7 (0.4, 151)	10.6 (0.3, 129)	7.9 (0.3, 181)
Week 0 of Maintenance
CDAI at Week 0, mean (SD)	117.6 (66.8)	125.4 (62.7)	111.6 (69.5)
SES-CD at Week 0, mean (SD)	7.8 (6.4)	8.3 (7.3)	7.3 (6.4)
SF at Week 0, mean (SD)	2.1 (1.9)	1.9 (1.7)	1.4 (1.7)
APS at Week 0, mean (SD)	0.6 (0.5)	0.6 (0.5)	0.6 (0.5)
FCP (mg/kg) at Week 0, median (min, max)	361 (30, 28800)	485.5 (30, 14804)	300.0 (30, 22912)
hs-CRP (mg/L) at Week 0, median (min, max)	3.7 (0, 48)	4.0 (0, 258)	3.6 (0, 42)

Baseline Characteristics	SKYRIZI 1200 mg IV N=646	PlaceboN=320
Female, %	41	38
Race (white), %	71	67
Median age, years	40	42
Median disease duration, years	6	6
Median weight, kg	70	71
Disease Extent
Left sided, %	48	46
Extensive/pancolitis, %	51	53
Median fecal calprotectin, mg/kg	1530 (n=598)	1624 (n=298)
Median hs-CRP, mg/L	3.4 (n=634)	4.0 (n=313)
Baseline immunosuppressant use, %	17	16
Baseline aminosalicylates use, %	73	73
Baseline corticosteroid use, %	36	35
Baseline Advanced Therapy Experience
Advanced therapy naïve,^a %	49	48
Advanced therapy failure,^b %	51	53
1	24	25
2	17	17
3+	11	11
Prior TNF use, %	86	84
Prior vedolizumab use, %	54	52
Prior JAK use, %	16	22
Baseline Modified Mayo Score
≤7, %	63	63
>7, %	38	37
Mean Mayo Endoscopy Subscore	2.7	2.7

EFFICACY DATA FOR CROHN'S DISEASE

Jump to:

Proven to Give Patients a Chance at Endoscopic Control and Durable Remission in Crohn's^1,2

Patients Achieved Visible Improvement of the Intestinal Lining and Clinical Remission^‡ at Weeks 12 and 52^1,5

SKYRIZI Is the Only IL-23i to Achieve Symptom Relief at Week 4 in Crohn’s IV Pivotal Trials^1,3,6

Remission as Early as Week 4⁶

Visible Improvement of the Intestinal Lining Up to ~5 years

**Endoscopic Remission* Seen at Weeks 12, 52, 152, and 248^1,2,4,5**

Endoscopic Response* at Weeks 52, 152, and 248^1,2,4,5

Durable Remission at 1 Year

**Clinical Remission* at Week 52^1,5**

Consistent Rates of Clinical Remission* Up to ~5 Years^1,2,4

Recommended for You

PATIENT-REPORTED SYMPTOM DATA AT Week 4

SF/APS MEASURES AT WEEK 4, INCLUDING POST HOC DATA FROM WEEKS 1-3^1,2

Patient-REPORTED SYMPTOM DATA AT Week 4

SF/APS Measures at Week 4, including post hoc data from weeks 1-3^1-3

Combined Clinical Response Data (CR-100) for Initial and Delayed Responders

~3 out of 4 (343/450) SKYRIZI Patients Experienced a Clinical Response (CR-100) at Week 12 or a Delayed Clinical Response at Week 24 in a Post Hoc Analysis^1,2

Open-Label Extension (OLE) Study Design

Key Baseline Characteristics Across the Study Populations^2,4-6

Open-Label Extension (OLE) Study Design

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

EFFICACY DATA FOR CROHN'S DISEASE

Jump to:

Proven to Give Patients a Chance at Endoscopic Control and Durable Remission in Crohn's1,2

Patients Achieved Visible Improvement of the Intestinal Lining and Clinical Remission‡ at Weeks 12 and 521,5

SKYRIZI Is the Only IL-23i to Achieve Symptom Relief at Week 4 in Crohn’s IV Pivotal Trials1,3,6

Remission as Early as Week 46

Visible Improvement of the Intestinal Lining Up to ~5 years

Endoscopic Remission* Seen at Weeks 12, 52, 152, and 2481,2,4,5

Endoscopic Response* at Weeks 52, 152, and 2481,2,4,5

Durable Remission at 1 Year

Clinical Remission* at Week 521,5

Consistent Rates of Clinical Remission* Up to ~5 Years1,2,4

Recommended for You

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

Proven to Give Patients a Chance at Endoscopic Control and Durable Remission in Crohn's^1,2

Patients Achieved Visible Improvement of the Intestinal Lining and Clinical Remission^‡ at Weeks 12 and 52^1,5

SKYRIZI Is the Only IL-23i to Achieve Symptom Relief at Week 4 in Crohn’s IV Pivotal Trials^1,3,6

Remission as Early as Week 4⁶

**Endoscopic Remission* Seen at Weeks 12, 52, 152, and 248^1,2,4,5**

Endoscopic Response* at Weeks 52, 152, and 248^1,2,4,5

**Clinical Remission* at Week 52^1,5**

Consistent Rates of Clinical Remission* Up to ~5 Years^1,2,4

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹